11/08/2025 IO Biotech's Cylembio + pembrolizumab demonstrated clinical improvement in PFS as a first-line treatment of Melanoma, but statistical significance was narrowly missed (Ref) IO Biotech announced topline results from the pivotal Phase 3 IOB-013 trial of Cylembio (imsapepimut and etimupepimut, adjuvanted; IDO and PD-L1 vaccine) + pembrolizumab vs pembrolizumab alone as a first-line treatment of advanced melanoma. The combo demonstrated clinical improvement in PFS vs p

In acknowledgment of Melanoma Awareness Month, Oncofocus presents a user-friendly infographic. It showcases a glimpse into top-level epidemiology data, key treatment options, and emerging therapies. Stay informed and help spread melanoma awareness with this publicly accessible infographic.